Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04336-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Chi-Hsien Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Cancer Vaccines, Dependovirus, Antigens, Neoplasm, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Medical University Hospital, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Therapeutic cancer vaccines, which induce anti-tumor immunity by targeting specific antigens, constitute a promising approach to cancer therapy. Our previous work developed a novel engineered adenovirus-associated virus 2 (AAV2)-based tumor-specific (neoantigen) cancer vaccine to boost antitumor immunity in combination with radiotherapy, resulting in tumor regression and less distant metastasis. However, the therapeutic efficacy of constitutive vector-based vaccination may be limited by poor immunogenicity, pre-existing vector-specific immunity, and vaccine-induced vector-specific immunity. Here, we examined the combinational therapeutic efficacy of AAV-based cancer vaccine, local radiotherapy, and immune checkpoint blockade (ICB) in different poorly immunogenic cancer animal models. We found that administration with AAV-based neoantigen vaccine significantly increased the response to radiotherapy and ICB, and decreased the risk of distant metastasis. Furthermore, we evaluated a heterologous prime-boost immunization strategy using two optimized AAV serotype vaccines to amplify tumor-specific immunity to neoantigens. These optimized AAV2/AAV6 neoantigen vaccine displayed strong immunogenicity with potent induction of CD8+ T cells. As combined with local radiotherapy, the prime-boost vaccine-induced superior tumor clearance and survival compared with other groups. Remarkably, optimized AAV2/AAV6 vaccination promoted CD8+ T-cell infiltration in the tumors and elicited the enrichment of T-cell clones. Furthermore, exhausted T-cell marker expression was significantly decreased in the tumor-infiltrating CD8+ T cells. Taken together, these results highlight the synergistic potency of engineered AAV2/AAV6 vaccines combined with local radiotherapy for poorly immunogenic cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
- Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
- Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, Taiwan.
- Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan.
- Institute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, HsinChu, Taiwan.
Förderung
- China Medical University Hospital
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Huang, C. H., Chen, J. Y., Chang, H. Y., Hong, W. Z., Jiang, Y. W., Lee, C. Y., Wu, C. H., Lin, Y. S., Tsai, Y. Y., Kao, W. L., Chao, K. S. C., & Huang, K. C. (2026). Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04336-9
Vancouver
Huang CH, Chen JY, Chang HY, Hong WZ, Jiang YW, Lee CY, et al. Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04336-9
BibTeX
@article{Huang2026,
author = {Huang, Chi-Hsien and Chen, Jhen-Yu and Chang, Hsin-Yu and Hong, Wei-Ze and Jiang, Yi-Wen and Lee, Chien-Yueh and Wu, Chia-Hsin and Lin, Yu-Sen and Tsai, Yuan-Yao and Kao, Wei-Ling and Chao, K S Clifford and Huang, Kevin Chih-Yang},
title = {Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04336-9}
}
EUVIMED